Alzamend Neuro furnishes Phase 1/2A lithium trial slides; differences not significant
On September 29, 2026, Alzamend Neuro furnished slides from a presentation by principal investigator Dr. Ovidiu C. Andronesi at the ISMRT conference on its Phase 1/2A trial of AL001, a lithium salt, compared with standard lithium carbonate (Li2CO3). The slides report only trends in a healthy-volunteer group, and the company states that differences between the two treatments are not statistically significant given the small sample. The filing does not disclose a financial effect, so the event is primarily early clinical data for shareholders to note.
Key points
- Presentation made on September 29, 2026 by Dr. Ovidiu C. Andronesi of Massachusetts General Hospital, who reports sponsored research funding from Alzamend Neuro.
- Trial design covers 30 participants: 6 healthy, 6 bipolar, 6 major depression, 6 Alzheimer and 6 PTSD, each receiving both AL001 and Li2CO3.
- Slides state the observed trends will be tested in subsequent patient cohorts.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.